Evidence map›Paper›PMID 40426194›Full record

ArticleBMC veterinary research2025

Sheep immune response against a novel recombinant enterotoxemia and infectious necrotic hepatitis vaccine in Türkiye.

Dilek Nur Ekinoğlu, Venhar Çelik, Esra Gül, Hakan Kalender, Hasan Öngör, Burhan Çetinkaya

Abstract read
In one paragraph

Article in BMC veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Dilek Nur Ekinoğlu *Graduate School of Natural and Applied Sciences, Firat University, Elazığ, Türkiye.
Venhar Çelik *Faculty of Engineering, Department of Bioengineering, Firat University, Elazığ, Türkiye. venharcelik@firat.edu.tr.
Esra Gül *Graduate School of Natural and Applied Sciences, Firat University, Elazığ, Türkiye.
Hakan Kalender *Faculty of Veterinary Medicine, Department of Microbiology, Firat University, Elazığ, Türkiye. hkalender@firat.edu.tr.
Hasan ÖngörFaculty of Veterinary Medicine, Department of Microbiology, Firat University, Elazığ, Türkiye.
Burhan ÇetinkayaFaculty of Veterinary Medicine, Department of Microbiology, Firat University, Elazığ, Türkiye.

Funding

The Scientific and Technological Research Council of Türkiye (TÜBİTAK) 121O666
6 · The paper itself

Abstract

backgroundClostridial diseases are common in ruminants all over the world. This study investigated the efficacy of a novel recombinant vaccine developed against enterotoxemia and infectious necrotic hepatitis in sheep.

resultsPlasmids carrying the Clostridium novyi type B alpha toxin gene (CnBtcn-alpha), Clostridium perfringens type C beta toxin gene (CpCcpb) and C. perfringens type D epsilon toxin gene (CpDetx) were constructed and the plasmids were transferred to Escherichia coli. Unpurified protein obtained from E. coli cell lysate supernatant was used to prepare the recombinant vaccine. The vaccine was prepared in three different formulas (RV100, RV200 and RV400), with 100, 200 and 400 µg of each protein in one vaccine dose. RV400 was preferred to immunise sheep as the antitoxin titres in the pooled blood serum of rabbits administered with this vaccine were determined to be above the minimum values specified in European Pharmacopoeia (10 IU/mL for beta, 5 IU/mL for epsilon, and 3.5 IU/mL for alpha). A total of 24 Akkaraman breed sheep with no antibodies against the relevant toxins were used for the experiment. All the animals in three groups (recombinant vaccine group, commercial polyvalent vaccine group and negative control group), each consisting of eight sheep, were vaccinated twice with an interval of 21 days and, the antitoxin titres were measured 14 days after the second vaccination by the mouse toxin neutralization test. The average antitoxin titres in sheep immunised with RV400 were calculated as 9.75 ± 1.28 IU/mL for C. perfringens beta, 13.75 ± 1.98 IU/mL for C. perfringens epsilon and 5.50 ± 0.93 IU/mL for C. novyi alpha toxins. On the other hand, the average values in sheep immunised with commercial vaccine were detected as 8.00 ± 2.14 IU/mL, 4.25 ± 1.67 IU/m L and 6.50 ± 0.93 IU/mL for C. perfringens beta, C. perfringens epsilon and C. novyi alpha, respectively. No antitoxin titre was detected in sheep in the negative control group (PBS). A statistically significant difference was observed between the recombinant and commercial vaccine groups in terms of C. perfringens epsilon antitoxin titres (P = 0.0002).

conclusionsThe present study was the first to investigate the efficacy of a combined recombinant vaccine prepared from unpurified proteins against enterotoxemia and infectious necrotic hepatitis and, the results suggested that it shows promise for protecting sheep against these diseases.

Indexed as

Bacterial VaccinesClostridium InfectionsEnterotoxemiaSheep DiseasesAnimalsAntibodies, BacterialBacterial ToxinsClostridium perfringensSheepVaccines, SyntheticAntibodies, BacterialBacterial ToxinsBacterial VaccinesVaccines, SyntheticEnterotoxemiaImmune responseInfectious necrotic hepatitisRecombinant vaccineSheep

Identifiers

PMID40426194
PMCPMC12117762

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.